Back to Journals » Clinical, Cosmetic and Investigational Dermatology » Volume 13

Impact of Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045% in the Management of Plaque Psoriasis in Adults

Authors Reddy V, Myers B, Yang EJ, Bhutani T

Received 21 April 2020

Accepted for publication 27 May 2020

Published 11 June 2020 Volume 2020:13 Pages 391—398

DOI https://doi.org/10.2147/CCID.S252426

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Jeffrey Weinberg


Vidhatha Reddy,1 Bridget Myers,1 Eric J Yang,2 Tina Bhutani1

1University of California, San Francisco, Department of Dermatology, San Francisco, CA, USA; 2Virginia Mason Medical Center, Seattle, WA, USA

Correspondence: Vidhatha Reddy
University of California, San Francisco, Department of Dermatology, 515 Spruce Street, San Francisco, CA 94118, USA
Email Vidhatha.reddy@ucsf.edu

Abstract: Halobetasol propionate and tazarotene lotion 0.01%/0.045% (HP/TAZ) is a topical medication approved for the treatment of plaque psoriasis in adults. As a treatment modality, HP/TAZ has a combinatory therapeutic effect because it contains both a corticosteroid (HP) and a retinoid (TAZ) component. Here, we review the important clinical efficacy and safety data derived from pivotal clinical trials for HP/TAZ in the treatment of plaque psoriasis. We also discuss the mechanism of action, dosage guidelines, pharmacokinetics/pharmacodynamics, and clinical considerations for HP/TAZ, including why HP/TAZ should be avoided in pregnant patients.

Keywords: halobetasol propionate, tazarotene, Duobrii, psoriasis, plaque, topical

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]